Background. The proliferative response induced by balloon angioplasty is known to be an important factor in the development of restenosis after successful coronary angioplasty.
Pe ercutaneous transluminal coronary angioplasty (PTCA) is a well-established method to reduce the severity of lesions in atherosclerotic coronary heart disease.",2 Its primary success rate approaches 90%. The long-term success of PTCA, however, is severely limited by the high incidence of restenosis, which occurs in up to 30-40% of primary successfully treated patients.3 6 Several experimental7 '8 and postmortem studies9-1" have demonstrated that restenosis after balloon angioplasty is caused by intimal proliferation of smooth muscle cells (SMCs) and platelet aggregation leading to mural thrombi.'213 Subsequent expression of growth factors, activation of mac-rophages and leukocytes, and expression of a variety of mitogens also occurs. [14] [15] [16] [17] [18] [19] In the past, different pharmacological interventions were performed to reduce the incidence of restenosis. Up to now, all compounds that were considered to reduce the incidence of restenosis failed in clinical studies. [20] [21] [22] [23] It has been shown, however, that heparin inhibits cellular proliferation and intimal thickening in experimental in vivo and in vitro studies. [24] [25] [26] The currently available clinical data on heparin and restenosis show conflicting results. In a preliminary See p 1632 study, Hirshfeld et a127 suggested that there may be a reduced incidence of restenosis after PTCA in patients with a prolonged heparin treatment after intervention, whereas in a study by Ellis et al,28 no reduction of restenosis was found. Clinical application of unfractionated heparin is limited, however, by the hazard of increased bleeding complications."
The pharmacological profiles of low-molecular-weight heparins (LMWH) are known to differ from those of unfractionated heparin, with a longer half-life and higher 
Bromodeoxyuridine Labeling
To determine the extent of cells undergoing DNA synthesis, BRDU, a thymidine analogue, was given to each animal 18 and 12 hours before excision of the vessels. As described earlier in detail,8 100 mg BRDU/kg body weight and 75 mg deoxycytidine/kg body weight (both from Sigma GmbH, Deisenhofen, FRG) were given as subcutaneous neck depot 18 hours (Figure 2 ). Staining of a-actin displayed a concentric intimal proliferation of SMCs with the greatest plaque size below the anode. The actin filaments in the plaque were found to be arranged homogeneously. Several foam cells could be identified predominantly in the central part of the plaque.
Compared with the control group without angioplasty, a progressive increase of intimal cell layers in the LMWH-untreated group was found up to 35±15 cell layers (p<0.01) after 28 days after balloon angioplasty. In this group, a stenosis of more than 50% luminal reduction caused by neointimal proliferation was observed in only one animal. As shown by a-actin staining, this lesion contained predominantly SMCs (Figure 3 ). In addition, a total occlusion caused by thrombus formation was found in three animals of this group (Table 1) .
Histological examination in the LMWH-treated animals revealed an increase of intimal wall thickness at 28 days after angioplasty (20±6 cell layers), which was significantly higher (p<0.05) than the control group without angioplasty. A significant lesion caused by neointimal proliferation or thrombus formation did not occur in the LMWH group. The difference in maximal extent of intimal cell layers at 28 days after balloon angioplasty between the LMWH-treated and nontreated groups, however, was statistically not significant. The frequency of thrombotic occlusions in the dilated arterial segments was not significantly higher (by Fisher's exact test) in the control group with angioplasty than in LMWH-treated animals.
Determination of intimal cell layers in animals treated with unfractionated heparin displayed a mean of 14±4 cell layers at 7 days after angioplasty, which was not significantly different from the control group without intervention ( was statistically significant (p < 0.01 at 3 days; p < 0.05 at 7 days). Quantification of the proliferative activity in animals treated with unfractionated heparin displayed an extent of 2.0±1.0% of cells undergoing DNA synthesis at 7 days after balloon treatment. The difference was statistically significant (p<0.05) compared with the control group without angioplasty. However, no statistically significant difference from the LMWH-treated group was found 7 days after angioplasty.
As shown in Table 2 , the average plasma anti-Xa activity increased from the baseline level before LMWH application (0±0 units/ml) to 0.73±0.18 units/ml at day 7 of LMWH treatment (p<0.001). In contrast, no significant change in the aPlT values was observed. A significant prolongation (p<0.01) of the aPlT time in animals that received unfractionated heparin from 16±2 seconds to 55±24 seconds was observed. In this group, however, plasma anti-Xa activities were increased (more than 1.0 unit/mI in all animals).
Discussion
It has been shown in animal models that SMC proliferation appears to be an acute event related to the initial injury with a peak maximum of proliferative activity of SMCs within the first 7 days after intervention.A 26 It is also known that heparin and its lowmolecular-weight fragments can inhibit proliferation of vascular SMCs in vitro and in vivo , 25 In addition to these antithrombotic properties, it has been shown that LMWH inhibits endothelial growth to a lesser extent than unfractionated heparin does in vitro.5253 It is speculated that the modulation of SMC proliferation might be induced by binding of several substances that interact with the endothelial lining (e.g., histamine, serotonin, thrombin, platelet-derived growth factor,5455 effect on components of the fibrinolytic system, plateletS,56 protein synthesis,49 and a direct inhibition of stimulated SMCs in the GI phase of mitosis. 43, 46 Growth-arrested SMCs in cell culture are 50-100 times more sensitive to the antiproliferative effects of heparin than are exponentially growing cells in culture. 44 Thus, it seems adequate and important to start with LMWH treatment before SMCs are activated by the vessel wall injury caused by PTCA.
In the present in vivo study comparing LMWHtreated and nontreated rabbits after balloon angioplasty, LMWH therapy resulted in a significantly reduced increase of intimal cells undergoing DNA synthesis in the early stage after dilatation.
Our study is limited, however, in regard to a further differentiation of the cell types involved in this process. It has been shown that macrophages within atherosclerotic lesions are capable of proliferation. In hypercholesterolemic rabbits, simultaneous thymidine autoradiography and immunostaining revealed that approximately 30% of the labeled cells were macrophages and 45% were SMCs.57 In addition, proliferating endothelial cells58 and lymphocytes59 might be also detected by thymidine or BRDU labeling after balloon angioplasty in experimental models.
In a recent study,8 we have shown a significant increase in the number of intimal cells undergoing DNA synthesis only within the first 7 days after balloon dilatation. Thus, LMWH administration in the present study was terminated 7 days after balloon angioplasty. In addition, it could be demonstrated that a significant increase of intimal cell layers occurred during the first 28 days after balloon dilatation.
No significant increase of intimal cell layers occurred from 28 to 42 days after intervention.8 Thus, the current study was terminated 28 days after balloon dilatation.
Determination of the anti-Xa activity in the LMWHtreated group displayed significantly increased levels of anti-Xa activity compared with the values before LMWH treatment. In addition, no changes were observed in aPTT values before and during LMWH treatment. The LMWH used in our experimental setting has been investigated in human cell cultures and demonstrated a significant inhibition of SMC proliferation without an effect on endothelial cells in vitro.3' Only limited information is available, however, about the effect of LMWH in vivo after balloon angioplasty. In a preliminary experimental study, Pow et aV60 reported a reduced incidence of restenosis after balloon angioplasty in rabbits by histological and angiographic criteria.
In addition to these results, we found an inhibition of cellular proliferation in the early stage after intervention. The reduced proliferative activity of SMCs resulted in only a moderate increase of intimal wall thickness after a 28-day control period after intervention. However, the difference in intimal cell layers after 28 days between the LMWH-treated and nontreated group was not statistically significant. Thus, although LMWH treatment resulted in a significant inhibition of cellular proliferation at 3 and 7 days after angioplasty, the effect on overall intimal wall thickness seems to be limited. This might be explained in part by migration of SMCs from the media in the intimal layer, as suggested by Clowes et al. 61 In the current study, unfractionated heparin was administered in one group for 7 days after dilatation to compare the effect of unfractionated heparin on cellular proliferation with the antiproliferative activity of LMWH. In agreement with several other in vivo studies,24-2656 a significant inhibition of cells undergoing DNA synthesis compared with the control group without pharmacological treatment was found. Determination of the aPTT before and during unfractionated heparin treatment, resulting in a significant prolongation of the aPTT time, has demonstrated plasma levels comparable to full heparin treatment in patients, as shown by a significant prolongation of the aPTT time.28 Anti-Xa activity was highly increased in this group, however, demonstrating that heparin was administered in the maximum possible dosage. Despite reduced interaction with blood coagulation, as indicated by an increase of anti-Xa activity without prolongation of the aPTT time, the significant inhibition of cellular proliferation observed in a human equivalent dosage of the compound62 supports the concept of prevention of restenosis by LMWH treatment in the early stage after PTCA.
In conclusion, our study shows that LMWH is useful for inhibition of cellular proliferation in the early stage after experimental angioplasty. The impact of LMWH treatment on the incidence of restenosis that occurs after angioplasty in humans, however, has to be determined in future clinical investigations.
